• Color Genomics Raises $45 Million To Expand Genetic Testing

    Bloomberg | Color Genomics Inc., the three-year-old startup aiming to democratize genetic testing, sealed $45 million in funding as it seeks to make its tests for cancer more affordable and accessible, the company announced Tuesday.

    Sep 27, 2016
  • Kite Unveils Anticipated CAR-T Cancer Data Positive But Not Complete

    Xconomy | Kite Pharma has dipped into a highly anticipated clinical trial of its cancer treatment, KTE-C19, to release a partial set of data. Although not complete, the data bolster the view that Kite could be the first among its peers to win the FDA's green light.

    Sep 27, 2016
  • The Sequencing App and the Quest for Fun

    Bio-IT World | The latest way to get into your genome is a $50 app-based venture that promises to give you a peek into your ancestry and tell you what kinds of bacteria you’re harboring in your mouth. Seeq launched earlier this month offering ultra-low coverage sequencing of the genome, oral microbiome sequencing, and ancestry reports. The goal is an extremely inexpensive infrastructure for people to get a little bit of genomic data and participate in research in a way that’s easy and fun.

    Sep 26, 2016
  • Top Scientists Cautious About Curing Cancer With Immunotherapy

    STAT | There's been a lot of excitement about immunotherapy as a tool to treat cancer. But top experts on Sunday struck an unexpected note of caution.

    Sep 26, 2016
  • New Genomics Pipeline Combines AWS, Local HPC, and Supercomputing

    HPCwire | Declining DNA sequencing costs and the rush to do whole genome sequencing (WGS) of large cohort populations presents an infrastructure challenge that some researchers are solving with a hybrid approach.

    Sep 23, 2016
  • When “Actionable” Genomic Sequencing Results Cannot Be Acted Upon

    JAMA Oncology | Brian J. Zikmund-Fisher recounts an interaction he had with a participant involved in genomic sequencing, in which the term “actionable” led to false hope and dashed expectations.

    Sep 23, 2016
  • Gilead Allergan Seen Trailing Intercept In Ongoing NASH Battle

    Investor's Business Daily | Gilead is trailing Intercept in the battle against NASH, Credit Suisse analyst Alethia Young said Thursday, two days after Botox maker Allergan jumped in.

    Sep 23, 2016